Microsure announced the closing of its Series B2 investment round, obtaining €38 million in development capital. With these funds, Microsure plans to complete the development of its MUSA-3 microsurgical robot for clinical studies, followed by FDA clearance in the USA and CE-mark in Europe. As part of this financing round, Kreske Nickelsen from the investor kineo will join the supervisory board.
The MUSA-3 microsurgical robot is being developed with features such as tremor reduction and integration with existing micro-instruments. It is designed for adaptability in various surgical procedures and offers improved ergonomics for surgeons, allowing them to work from a console with digital exoscopes or surgical microscopes.
The recent financing round includes new investors such as the European Innovation Council Fund (EICF), kineo, Invest-NL, and several private investor groups. Existing shareholders supporting Microsure include Innovation Industries, BOM Ventures, Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e), and Microsure Founders. The funds will contribute to the company’s financial foundation.
Microsure has received an EIC Accelerator grant and an Innovation Loan from RvO, a division of the Dutch Ministry of Economic Affairs. The company has also entered into a financing agreement with kineo, allowing for potential leasing options for hospitals interested in MUSA-3.
Microsure has previously conducted clinical studies with the MUSA-2 prototype at Maastricht University Medical Center in the Netherlands and Uppsala Academic Hospital in Sweden. These studies encompassed various surgical indications and provided feedback for MUSA-3’s development. There were also in-vitro studies focused on the benefits of the technology.
Professor Peter Neligan commented on Microsure’s contributions to microsurgery, emphasizing their dedication to precision and the potential impacts of their technologies.
Svetoslava Georgieva, Chair of the EIC Fund Board, stated that the EIC Fund Board supports Microsure in this investment round and looks forward to the introduction of MUSA-3 to the EU markets.
Sjaak Deckers, CEO of Microsure, expressed gratitude to the investors for their support, emphasizing the company’s objective to further develop its technology and introduce MUSA-3 globally.